English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Sofosbuvir is a viral polymerase nucleotide inhibitor that was approved in December 2013 by the United States Food and Drug Administration (FDA), and in January 2014 by the European Medicines Agency for the treatment of HCV infection1. The WHO Guidelines for the screening, care and treatment of persons with hepatitis C infection recommend sofosbuvir in combination with ribavirin in genotypes 1, 2, 3 and 4 HCV infection, either with or without pegylated interferon (depending on the HCV genotype)7. Sofosbuvir in combination with ribavirin is the first interferon-free HCV treatment. The fact that sofosbuvir is all oral simplifies the treatment and will allow expansion in low resource settings with poor health infrastructure.  The objective of this paper identify the most relevant process patents with respect to the medicines identify in which countries these patents have been filed and granted  This Article study mainly find numerous patents relating to preparation of  Sofosbuvir. These patents will cover different aspects and innovations around the same product. Not all however are equally relevant, as many will cover variations or production processes but would not prevent somebody else to produce the medicine, e.g. by using a different process.

Chronic Hepatitis (Chc), Viral Polymerase Nucleotide Inhibitor & Process Patents Review and Evaluation, Preparation of Sofosbuvir